{"Symbol": "ALT", "AssetType": "Common Stock", "Name": "Altimmune Inc", "Description": "Altimmune, Inc., a clinical-stage biopharmaceutical company, focuses on the development of intranasal vaccines, immunomodulatory therapies, and treatments for liver disease. The company is headquartered in Gaithersburg, Maryland.", "CIK": "1326190", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "HEALTHCARE", "Industry": "BIOTECHNOLOGY", "Address": "910 CLOPPER ROAD, GAITHERSBURG, MD, UNITED STATES, 20878", "OfficialSite": "https://altimmune.com", "FiscalYearEnd": "December", "LatestQuarter": "2025-09-30", "MarketCapitalization": "567299000", "EBITDA": "-90343000", "PERatio": "None", "PEGRatio": "0", "BookValue": "1.941", "DividendPerShare": "None", "DividendYield": "None", "EPS": "-1.07", "RevenuePerShareTTM": "0", "ProfitMargin": "0", "OperatingMarginTTM": "-4171.8", "ReturnOnAssetsTTM": "-0.309", "ReturnOnEquityTTM": "-0.526", "RevenueTTM": "20000", "GrossProfitTTM": "-67784000", "DilutedEPSTTM": "-1.07", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "0", "AnalystTargetPrice": "17.67", "AnalystRatingStrongBuy": "3", "AnalystRatingBuy": "5", "AnalystRatingHold": "1", "AnalystRatingSell": "1", "AnalystRatingStrongSell": "0", "TrailingPE": "-", "ForwardPE": "-", "PriceToSalesRatioTTM": "28364.94", "PriceToBookRatio": "3.057", "EVToRevenue": "18621.39", "EVToEBITDA": "-4.2", "Beta": "0.076", "52WeekHigh": "7.73", "52WeekLow": "2.9", "50DayMovingAverage": "4.701", "200DayMovingAverage": "4.554", "SharesOutstanding": "125232000", "SharesFloat": "103533000", "PercentInsiders": "0.698", "PercentInstitutions": "48.799", "DividendDate": "2018-09-14", "ExDividendDate": "2017-01-20"}